Serum micrornas as tool to predict early response to benralizumab in severe eosinophilic asthma
AuthorCañas, José A.; Valverde-Monge, Marcela; Rodrigo-Muñoz, José M.; Sastre, Beatriz; Gil-Martínez, Marta; García-Latorre, Raquel; Rial, Manuel J.; Gómez-Cardeñosa, Aida; Fernández-Nieto, Mar; Pinillos-Robles, Erwin J.; Rodríguez-Nieto, María J.; González Mangado, Nicolás; Sastre Domínguez, Joaquín; Del Pozo, Victoria
EntityUAM. Departamento de Medicina; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)
10.3390/jpm11020076Journal of Personalized Medicine 11.2 (2921): 76
Funded byThis manuscript was funded by Fondo de Investigación Sanitaria–FIS and FEDER (Fondo Europeo de Desarrollo Regional) [PI15/00803, PI18/00044, and FI16/00036], CIBER de Enfermedades Respiratorias (CIBERES), Merck Health Foundation funds, and Ministerio de Ciencia, Innovación y Universidades (RTC-2017-6501-1)
ProjectGobierno de España. PI15/00803; Gobierno de España. PI18/00044; Gobierno de España. FI16/00036; Gobierno de España. RTC-2017-6501-1
SubjectsBenralizumab; Biologic treatment; MicroRNA; Severe eosinophilic asthma; Medicina
Rights© 2021 The authors
Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eight weeks of therapy, and a correlation was found between miR-1246 and eosinophil counts, including a number of exacerbations per year in these severe asthmatics. In silico pathway analysis revealed that these three miRNAs are regulators of the MAPK signaling pathway, regulating target genes implicated in asthma such as NFKB2, NFATC3, DUSP1, DUSP2, DUSP5 and DUSP16. In this study, we observed an altered expression of miR-1246, miR-5100 and miR-338-3p after eight weeks of benralizumab administration, which could be used as early response markers.
Google Scholar:Cañas, José A. - Valverde-Monge, Marcela - Rodrigo-Muñoz, José M. - Sastre, Beatriz - Gil-Martínez, Marta - García-Latorre, Raquel - Rial, Manuel J. - Gómez-Cardeñosa, Aida - Fernández-Nieto, Mar - Pinillos-Robles, Erwin J. - Rodríguez-Nieto, María J. - González Mangado, Nicolás - Sastre Domínguez, Joaquín - Del Pozo, Victoria
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.